---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008380"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:12:17.639886+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines

## Summary
- Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.
- Cash, cash equivalents and marketable securities $204.4M; ATM raised $26.7M net in April, extending runway through end-2025.
- Zunsemetinib RA Phase 2b data guided to Q4 2023; PsA Phase 2a data delayed to H1 2024 (from YE 2023) due to slow European enrollment.
- ATI-1777 AD Phase 2b data now expected H2 2023 (from mid-year) after protocol expansion to include milder disease.
- ATI-2138 MAD data on track for H2 2023; ulcerative colitis selected as first development target.

## SEC filing metadata
- accession: 0001558370-23-008380
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/0001558370-23-008380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/acrs-20230508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008380
- JSON: https://secwatch.observer/filing/0001558370-23-008380.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008380.txt

## Key facts
- Earnings Releases
  Aclaris Therapeutics, Inc. reported the first quarter of 2023 results: revenue $2.5 million, net income Net loss was $28.2 million.
  - Period: the first quarter of 2023
  - Revenue: $2.5 million
  - Net income: Net loss was $28.2 million
  - Result: reported results
  source text: ​ Financial Results First Quarter 2023 ● Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. ​ ● Total revenue was $2.5 million for the first quarter of 2023 compared to $1.5 million for the first quarter of 2022. The increase was driven primarily by higher licensing revenues from royalties earned on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/0001558370-23-008380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.